Page 2 - Nasdaq Moln News Today

Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 20,600 shares, an increase of 32.1% from the March 15th total of 15,600 shares. Based on an average trading volume of 2,200 shares, the […]

Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 20,600 shares, an increase of 32.1% from the March 15th total of 15,600 shares. Based on an average daily volume of 2,200 shares, the […]

Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 20,600 shares, a growth of 32.1% from the March 15th total of 15,600 shares. Based on an average daily volume of 2,200 shares, the […]

Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues...

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagersTri-specific T-cell engager resulted...

Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 16,200 shares, an increase of 76.1% from the May 15th total of 9,200 shares. Based on an average daily volume of 25,900 shares, the […]

Molecular Partners (NASDAQ:MOLN – Get Rating) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership. Profitability This table compares Molecular Partners and Brainstorm […]

Molecular Partners (NASDAQ:MOLN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as DARPin(R) therapeutics. Molecular […]

Molecular Partners (NASDAQ:MOLN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as […]

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 23, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a...